Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Novo Nordisk A/S (NVO) Price & Performance

BioNTech SE - ADRTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Novo Nordisk A/S — how do they compare? BioNTech SE - ADR trades at $93.4 (market cap $23.31B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.9× BioNTech SE - ADR's market cap, and Novo Nordisk A/S pays a 3.81% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXNVO
Market Cap
$23.31B$207.85B
Sector
HealthHealth
52-Week High
$119.34$63.98
52-Week Low
$83.89$35.29
Enterprise Value
$6.60B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO